Use of a Multigene Prognostic Assay for Selection of Adjuvant Chemotherapy in Patients With Stage II Colon Cancer: Impact on Quality-Adjusted Life Expectancy and Costs.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2011.29.4_suppl.491
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)


Related search